Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Unveils $1.5 Billion Expansion In China With New Beijing R&D Center; Plans To Double R&D Team By 2014

This article was originally published in PharmAsia News

Executive Summary

While many Big Pharmas are cutting R&D budgets in response to patent cliffs, Merck is investing $1.5 billion in R&D in China, in what could be the largest ever pharma R&D investment in the country.

You may also be interested in...



Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity

BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country

Merck And BGI Sign Global Deal Focused On Biomarkers, Genomics

After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies

Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley

BEIJING - Aiming to carve a leading position in China's nascent biotech industry, Beijing has embarked on a project to grow the industry more than two-fold in three years. Dubbed the "G20 Project," the Beijing Leap-forward Development Program for Biopharmaceutical Industry seeks to transform the capital city into China's hub for biotech R&D and manufacturing

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC077046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel